Cassava Sciences's Total Assets for the quarter that ended in Dec. 2023 was $151.66 Mil.
During the past 12 months, Cassava Sciences's average Total Assets Growth Rate was -9.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 237.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 210.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 65.10% per year.
During the past 13 years, Cassava Sciences's highest 3-Year average Total Assets Growth Rate was 364.80%. The lowest was -67.80%. And the median was 2.90%.
Total Assets is connected with ROA %. Cassava Sciences's annualizedROA % for the quarter that ended in Dec. 2023 was -51.62%. Total Assets is also linked to Revenue through Asset Turnover. Cassava Sciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
Cassava Sciences Total Assets Historical Data
The historical data trend for Cassava Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cassava Sciences Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
23.49
94.30
266.78
234.83
151.66
Cassava Sciences Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
234.83
218.11
197.25
172.53
151.66
Cassava Sciences Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cassava Sciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cassava Sciences (NAS:SAVA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cassava Sciences's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cassava Sciences Total Assets Related Terms
Thank you for viewing the detailed overview of Cassava Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Cassava Sciences (Cassava Sciences) Business Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAVA has been successfully added to your 